Drug recall · November 4, 2026
Olmesartan Medoxomil recall
Why: Failed Dissolution Specifications.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12.5mg, packaged as a) 30-count bottle, NDC 33342-246-07; b) 90-count bottle, NDC 33342-246-10; Rx Only, Manufactured for : Macleods Pharma USA, Inc. Princeton, NJ 08540, Manufactured by: Macleods Pharmaceuticals Ltd, Daman, 396210, India
- Lots / codes
Lot #: a) 12251163A, Exp 05-31-2027; b) 12251163B, Exp 05-31-2027
- Quantity
- 3528 30-count and 216 90-count bottles
- Company
- Macleods Pharma USA, Inc, Princeton, NJ
- Distribution
- Nationwide in the USA
- Initiated
- October 7, 2026 · Voluntary: Firm initiated
- Classified
- October 26, 2026
- Reported
- November 4, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amlodipine / hydrochlorothiazide / olmesartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.